Feb 18, 2026Partial Epigenetic Reprogramming for Vision Loss: Life Biosciences ER-100 TrialLife Biosciences received FDA clearance to begin the first human trial of partial epigenetic reprogramming using OSK Yamanaka factors delivered via AAV for glaucoma and NAION. Trial is in early stages; no human efficacy data exists yet.